# Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

> **NCT00874419** · PHASE3 · COMPLETED · sponsor: **Tongji University** · enrollment: 165 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib
- **DRUG:** gemcitabine/carboplatin

## Key facts

- **NCT ID:** NCT00874419
- **Lead sponsor:** Tongji University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-07
- **Final completion:** 2012-07
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2014-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874419, "Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00874419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*